We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
AstraZeneca and Sanofi said an ongoing phase 3 study has shown that their investigational antibody, nirsevimab, can prevent respiratory syncytial virus (RSV) infections in infants. Read More
Bristol Myers Squibb (BMS) has reported positive findings from two late-stage clinical trials of deucravacitinib, its experimental treatment for moderate-to-severe plaque psoriasis. Read More
Syndax Pharmaceuticals announced that its targeted cancer therapy, SNDX-5613, induced complete remission for certain advanced leukemia patients in an early-stage study. Read More
Novartis has released new data from a late-stage study showing that its multiple sclerosis (MS) drug Kesimpta (ofatumumab) reduced the risk of disease progression. Read More
Merck has decided to end research and development on MK-7110, an experimental oral drug for treatment of hospitalized coronavirus patients that had shown promise in a late-stage trial. Read More